Physician profile
Eric J Quartetti
NPI 1104985159
$1,055.56
in general payments reported to CMS, 2019-2025
16 companies · $52.64 in 2025
The $52.64 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $157 · 2022: $170 · 2023: $185 · 2024: $304 · 2025: $52.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $540.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $211.31 | 2019-2024 | Rocklatan |
| Rxsight INC | $117.81 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Bausch & Lomb Americas INC. | $109.91 | 2022-2024 | Alrex, Lotemax Sm, Vyzulta |
| Sun Pharmaceutical Industries INC. | $107.34 | 2019-2025 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $105.94 | 2020 | |
| Oyster Point Pharma, INC. | $91.28 | 2022-2024 | Ryzumvi, Tyrvaya |
| Abbvie INC. | $56.94 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $40.22 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $36.90 | 2024 | Eylea, Eylea Hd |
| Ocular Therapeutix, INC. | $33.52 | 2023 | Dextenza |
| Allergan, INC. | $32.23 | 2020-2022 | |
| Apellis Pharmaceuticals, INC. | $31.30 | 2023 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $26.56 | 2024 | Xdemvy |
| Biotissue Holdings INC. | $24.85 | 2019 | |
| Thea Pharma INC. | $24.27 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $5.18 | 2025 | Clearpath, Via360, Streamline |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Quartetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.